Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carboplatin and etoposide. Ivonescimab is a type of drug called a bispecific antibody. Antibodies are proteins that specifically recognize and bind to other types of proteins called antigens. Antibodies and antigens can work together to help the immune system fight cancer cells. Bispecific antibody, meaning it targets two different molecules at the same time. Ivonescimab is a new drug that may help the immune system attack cancer cells and may also block certain pathways that cancer uses to grow and spread. This dual action of ivonescimab aims to help the immune system to fight the cancer and also disrupt tumor growth by blocking blood vessel formation that tumors use to grow. Participants will receive induction with 4 cycles of ivonescimab (dose determined by randomization) with standard of care carboplatin and etoposide followed by maintenance therapy with ivonescimab at the same dose received during induction. Treatment will continue until disease progression, unacceptable toxicity or participant withdrawal. The purpose of this study is to determine what dose of ivonescimab works best in combination with carboplatin and etoposide chemotherapy in ES-SCLC. We will also examine the side effects, good and bad, associated with ivonescimab.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony laboratoryjnie zaawansowany drobnokomórkowy rak płuca.
- •Brak wcześniejszego leczenia systemowego tej choroby.
- •Choroba widoczna w badaniach obrazowych.
- •Wiek 18 lat lub więcej.
- •Dobry ogólny stan zdrowia (w skali ECOG 0-1).
- •Sprawnie działające narządy i szpik kostny (badania krwi i nerek w normie).
- •Zgoda na udział i podpisanie formularza świadomej zgody.
- •Chęć przekazania materiału biologicznego do badań.
✗ Disqualifies
- •Ciąża lub karmienie piersią.
- •Kobiety i mężczyźni nie stosujący skutecznych metod antykoncepcji lub abstynencji seksualnej podczas badania i przez 120 dni po ostatniej dawce leku.
- •Ostatnia transfuzja krwi lub stosowanie czynników wzrostu poniżej 7 dni przed badaniami.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (11)
University of Miami
Miami, United States
University of Maryland
Baltimore, United States
Morristown Medical Center
Morristown, United States
Rutgers Cancer Institute
New Brunswick, United States
Montefiore Medical Center- Montefiore Medical Park
The Bronx, United States
Ohio State Univerity
Columbus, United States
Fox Chase Cancer Center
Philadelphia, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
Guthrie
Sayre, United States
Universtiy of Virginia
Charlottesville, United States
Aspirus Cancer Center Wausau
Wausau, United States
Trial contact
Rucha Shah, MS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.